Vesalius Biocapital III

Memo Therapeutics AG initiates phase 1 clinical study of MTX-005 against BK virus infection. Read more ...!

OncoDNA and Synlab Partner to Facilitate Access to Comprehensive Biomarker Testing for Cancer Therapy Selection in Germany. Read more ...!

Rejuvenate Biomed NV - a biomedical company developing novel combination drugs for age-related diseases, provides an update on its development pipeline and strategy. Read more ...!

CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L‘Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Read more ...!

Industry expert Peter Fröhlingsdorf is the new Managing Director of Munich-based MedTech company Mecuris. Read more ...!

Paralympic cyclist Denise Schindler is new brand ambassador for Medtech startup Mecuris GmbH, a Munich-based medical technology start-up focusing on the digitization of prostheses and orthoses. Read more ...!

Vesalius Biocapital | Vintage 2017: €65 million assets under management (first closing)In investment mode.

Contact information Vesalius Biocapital Partners III Sarl: 15 Rue de L‘Industrie, L – 8069 Bertrange, Luxemburg

Vesalius Biocapital is a European life sciences venture capital investor. The active fund Vesalius Biocapital III had a first closing in May 2017 – currently, over € 75 million are managed.

Vesalius Biocapital: The operators of this website take the protection of your personal data very seriously. We treat your personal data confidential and according to the legal data protection regulations and this Privacy Policy